REVB
NASDAQ · Biotechnology
Revelation Biosciences Inc
$1.13
+0.00 (+0.00%)
Financial Highlights (FY 2025)
Revenue
725.2K
Net Income
-167,658
Gross Margin
52.4%
Profit Margin
-23.1%
Rev Growth
-8.8%
D/E Ratio
0.76
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 52.4% | 52.4% | 52.4% |
| Operating Margin | -25.7% | -27.7% | -24.3% |
| Profit Margin | -23.1% | -28.7% | -31.3% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 725.2K | 710.5K | 685.3K |
| Gross Profit | 380.4K | 372.7K | 359.4K |
| Operating Income | -186,726 | -197,170 | -166,298 |
| Net Income | -167,658 | -204,058 | -214,742 |
| Gross Margin | 52.4% | 52.4% | 52.4% |
| Operating Margin | -25.7% | -27.7% | -24.3% |
| Profit Margin | -23.1% | -28.7% | -31.3% |
| Rev Growth | -8.8% | +0.9% | +1.6% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 1.22M | 1.04M | 1.16M |
| Total Equity | 1.60M | 1.66M | 1.64M |
| D/E Ratio | 0.76 | 0.62 | 0.70 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -214,609 | -243,655 | -229,479 |
| Free Cash Flow | -113,026 | -111,014 | -146,791 |